Identification of a predominant isolate of Mycobacterium tuberculosis using molecular and clinical epidemiology tools and in vitro cytokine responses

BMC Infectious Diseases

A Kabani²  E Hershfield²  J Wolfe³  A Al-Azem¹  M Kaushal Sharma³ 

[1]Clinical Microbiology, Health Sciences Center, Winnipeg, MB, Canada

[2]Faculty of Medicine, University of Manitoba, Winnipeg, Canada

[3]National Reference Centre for Mycobacteriology, National Microbiology Laboratories, Health Canada, 1015 Arlington Street, Winnipeg, Canada

关键词: tumor necrosis factor-α;    interferon-γ;    IL-10;    IL-1β;    Type1 strain-Manitoba;    Mycobacterium tuberculosis-epidemiology;    Mycobacterium tuberculosis-immunology;   

Others  :  1177135
DOI  :  10.1186/1471-2334-3-3

 received in 2002-11-18, accepted in 2003-04-08,  发布年份 2003

【 摘 要 】

Background

Tuberculosis (TB) surveillance programs in Canada have established that TB in Canada is becoming a disease of geographically and demographically distinct groups. In 1995, treaty status aboriginals from the province of Manitoba accounted for 46% of the disease burden of this sub-group in Canada. The TB incidence rates are dramatically high in certain reserves of Manitoba and are equivalent to rates in African countries. The objective of our study was to identify prevalent isolates of Mycobacterium tuberculosis in the patient population of Manitoba using molecular epidemiology tools, studying the patient demographics associated with the prevalent strain and studying the in vitro cytokine profiles post-infection with the predominant strain.

Methods

Molecular typing was performed on all isolates available between 1992 to1997. A clinical database was generated using patient information from Manitoba. THP-1 cells were infected using strains of M. tuberculosis and cytokine profiles were determined using immunoassays for cytokines IL-1β, IL-10, IL-12, IFN-γ and TNF-α.

Results

In Manitoba, 24% of the disease burden is due to a particular M. tuberculosis strain (Type1). The strain is common in patients of aboriginal decent and is responsible for at least 87% of these cases. Cytokine assays indicate that the Type1 strain induces comparatively lower titers of IL-1β, IFN-γ and TNF-α in infected THP-1 cells as compared to H37Ra and H37Rv strains.

Conclusion

In Manitoba, Type1 strain is predominant in TB patients. The majority of the cases infected with this particular strain are newly active with a high incidence of respiratory disease, positive chest radiographs and pulmonary cavities. In vitro secretion of IL-1β, IFN-γ and TNF-α is suppressed in Type1 infected culture samples when compared to H37Ra and H37Rv infected cells.

【 授权许可】

   
2003 Sharma et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Fanning EA: Globalization of tuberculosis [editorial; comment]. CMAJ 1998, 158:611-612.
• [2]Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A: Secular trends of tuberculosis in western Europe. Bull World Health Organ 1993, 71(3–4):297-306.
• [3]Al-Azem A, Elliot L, Hershfield E, Blackwood K, Kabani A: Conventional and Molecular Epidemiology of Tuberculosis in Manitoba. Int J Tuberc Lung Dis 2002, in press.
• [4]Al-Azem AA, Hershfield ES, Sharma M, Wolfe J, Macmorran J, Hoban DJ, Kabani A: Clinical and Molecular Epidemiology of Tuberculosis in Manitoba. Community-Acquired Infections and Related Epidemiological Studies 2000, 585-585.
• [5]Long R, Njoo H, Hershfield E: Tuberculosis: 3. Epidemiology of the disease in Canada. CMAJ 1999, 160:1185-1190.
• [6]Long R, Sutherland K, Kunimoto D, Cowie R, Manfreda J: The epidemiology of tuberculosis among foreign-born persons in Alberta, Canada, 1989–1998: identification of high risk groups. Int J Tuberc Lung Dis 2002, 6:615-621.
• [7]Cohn DL, O'Brien RJ: The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998, 2:16-26.
• [8]Small PM, Hopewell PC, Samir MD, Singh P, Paz A, Parsonnet J, Ruston DC, Gisela BS, Schecter F, Daley CL, Schoolnik G: A Population-Based Study Using Conventional and Molecular Methods. New England Journal of Medicine 9940, 330:1703-1709.
• [9]Clarridge JE III, Shawar RM, Shinnick TM, Plikaytis BB: Large-scale use of polymerase chain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory. J Clin Microbiol 1993, 31:2049-2056.
• [10]van-Soolingen D, Qian L, de-Haas PE, Douglas JT, Traore H, Portaels F, Qing HZ, Enkhsaikan D, Nymadawa P, van-Embden JD: Predominance of a single genotype of Mycobacterium tuberculosis in countries of east Asia. J Clin Microbiol 1995, 33:3234-3238.
• [11]van-Soolingen D, Hermans PW, de-Haas PE, Soll DR, van-Embden JD: Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991, 29:2578-2586.
• [12]Chevrel DD, Abderrahman A, Haltiti R, Koubaji H, Gicquel B, Dellagi K: Large-scale DNA fingerprinting of Mycobacterium tuberculosis strains as a tool for epidemiological studies of tuberculosis. J Clin Microbiol 1993, 31:2446-2450.
• [13]Eisenach KD, Crawford JT, Bates JH: Genetic Relatedness among Sttrains of the Mycobacterium tuberculosis Complex. Am Rev Respir Dis 1986, 1065-1068.
• [14]Soini H, Pan X, Teeter L, Musser JM, Graviss EA: Transmission dynamics and molecular characterization of Mycobacterium tuberculosis isolates with low copy numbers of IS6110. Journal Of Clinical Microbiology 1901, 39:217-221.
• [15]Barnes PF, Chatterjee D, Abrams JS, Lu S, Wang E, Yamamura M, Brennan PJ, Modlin RL: Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol 1992, 149:541-547.
• [16]Barnes PF, Modlin RL: Human cellular immune responses to Mycobacterium tuberculosis. Curr Top Microbiol Immunol 1996, 215:197-219.
• [17]Skamene E, Schurr E, Gros P: Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections. Annu Rev Med 1998, 49:275-287.
• [18]Qureshi ST, Skamene E, Malo D: Comparative genomics and host resistance against infectious diseases. Emerg Infect Dis 1999, 5:36-47.
• [19]Lucey DR, Clerici M, Shearer GM: Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996, 9:532-562.
• [20]Elliott AM, Hurst TJ, Balyeku MN, Quigley MA, Kaleebu P, French N, Biryahwaho B, Whitworth JA, Dockrell HM, Hayes RJ: The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study. Int J Tuberc Lung Dis 1999, 3:239-247.
• [21]Flesch IE, Kaufmann SH: Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. Infect Immun 1990, 58:2675-2677.
• [22]van-Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach KD, Gicquel B, Hermans P, Martin C, McAdam R, Shinnick TM, et al.: Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology [see comments]. J Clin Microbiol 1993, 31:406-409.
• [23]Zimmerli S, Edwards S, Ernst JD: Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am J Respir Cell Mol Biol 1996, 15:760-770.
• [24]Fulton SA, Johnsen JM, Wolf SF, Sieburth DS, Boom WH: Interleukin-12 production by human monocytes infected with Mycobacterium tuberculosis: role of phagocytosis. Infect Immun 1996, 64:2523-2531.
• [25]Aso H, Yoshite O, Tomioka Y, Rose MT, Mizugaki M: A 63 kDa tumor necrosis factor inhibitor released from a human monocytic leukemia cell line, THP-1. Microbiol Immunol 1999, 43:53-59.
• [26]Valway SE, Sanchez MPC, Shinnick TF, Orme I, Agerton T, Hoy D, Jones S, Westmoreland H, Onorato M: An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med 1998, 338:633-638.
• [27]Arvanitakis Z, Long RL, Hershfield ES, Manfreda J, Kabani A, Kunimoto D, Power C: M. tuberculosis molecular variation in CNS infection: evidence for strain-dependent neurovirulence. Neurology 1998, 50:1827-1832.
• [28]Manca C, Tsenova L, Barry CE, Bergtold A, Freeman S, Haslett PA, Musser JM, Freedman VH, Kaplan G: Mycobacterium tuberculosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J Immunol 1999, 162:6740-6746.
• [29]Manca C, Tsenova L, Bergtold A, Freeman S, Tovey M, Musser JM, Barry CE III, Freedman VH, Kaplan G: Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A 2001, 98:5752-5757.
• [30]Flesch IE, Hess JH, Huang S, Aguet M, Rothe J, Bluethmann H, Kaufmann SH: Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995, 181:1615-1621.
• [31]Romani L, Puccetti P, Bistoni F: Interleukin-12 in infectious diseases. Clin Microbiol Rev 1997, 10:611-636.
• [32]Chan J, Xing Y, Magliozzo RS, Bloom BR: Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992, 175:1111-1122.
• [33]Flesch IE, Kaufmann SH: Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun 1991, 59:3213-3218.
• [34]Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR: An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993, 178:2249-2254.
• [35]Chensue SW, Warmington KS, Ruth JH, Lincoln P, Kunkel SL: Cytokine function during mycobacterial and schistosomal antigen-induced pulmonary granuloma formation. Local and regional participation of IFN-gamma, IL-10, and TNF. J Immunol 1995, 154:5969-5976.
• [36]Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM: Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993, 178:2243-2247.
• [37]Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2:561-572.
• [38]Johnson BJ, McMurray DN: Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytes. Infect Immun 1994, 62:1444-1450.
• [39]Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 1991, 174:1549-1555.
• [40]Zhang M, Gong J, Yang Z, Samten B, Cave MD, Barnes PF: Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis 1999, 179:1213-1217.
• [41]Barnes PF, Wizel B: Type 1 cytokines and the pathogenesis of tuberculosis. American Journal Of Respiratory And Critical Care Medicine 2000, 161:1773-1774.